Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · April 26, 2024

Outcomes of Women With HR+/HER2− Advanced Breast Cancer Receiving Gedatolisib Combined With Palbociclib and Endocrine Therapy

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study
Lancet Oncol 2024 Apr 01;25(4)474-487, RM Layman, HS Han, HS Rugo, EM Stringer-Reasor, JM Specht, EC Dees, P Kabos, S Suzuki, SC Mutka, BF Sullivan, I Gorbatchevsky, R Wesolowski

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading